Trastuzumab therapy for tamoxifen-stimulated endometrial cancer

Cancer Research

Volumn 65, Issue 18, 2005, Pages 8504-8513

  Osipo, Clodia ^a   Meeke, Kathleen ^a   Liu, Hong ^a   Cheng, Dong ^a   Lim, Sherry ^a   Weichel, Alyssa ^a   Jordan, V Craig ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR ALPHA; INSULIN RECEPTOR SUBSTRATE 1; PROTEIN KINASE B; PROTEIN PS2; RALOXIFENE; SOMATOMEDIN; SOMATOMEDIN C; TAMOXIFEN; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED CANCER; DRUG MECHANISM; ENDOMETRIUM CANCER; ESTROGEN ACTIVITY; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE C MYC; ONCOGENE NEU; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; ENDOMETRIAL NEOPLASMS; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; PRESENILIN-2; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, ERBB-2; RNA, MESSENGER; STIMULATION, CHEMICAL; TAMOXIFEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 24944590694     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-4107     Document Type: Article

References (54)

1. Jordan VC. Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell 2004;5:207-13.
2. Fisher B, Redmond C, Brown A, et al. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J Clin Oncol 1986;4:459-71.
3. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
4. Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 1988;48:812-5.
5. Jordan VC. Selective estrogen receptor modulation: a personal perspective. Cancer Res 2001;61:5683-7.
6. Kristensen B, Ejlertsen B, Dalgaard P, et al. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J Clin Oncol 1994;12:992-7.
7. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Ames RW, Reid IR. The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. Am J Med 1995;99:636-41.
8. Love RR, Wiebe DA, Feyzi JM, Newcomb PA, Chappell RJ. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 1994;86:1534-9.
9. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-37.
10. Liehr JG. Genotoxicity of the steroidal oestrogens oestrone and oestradiol: possible mechanism of uterine and mammary cancer development. Hum Reprod Update 2001;7:273-81.
11. Carthew P, Lee PN, Edwards RE, Heydon RT, Nolan BM, Martin EA. Cumulative exposure to tamoxifen: DNA adducts and liver cancer in the rat. Arch Toxicol 2001;75:375-80.
12. Beland FA, Churchwell MI, Doerge DR, et al. Electrospray ionization-tandem mass spectrometry and 32P-postlabeling analyses of tamoxifen-DNA adducts in humans. J Natl Cancer Inst 2004;96:1099-104.
13. White IN. Tamoxifen: is it safe? Comparison of activation and detoxication mechanisms in rodents and in humans. Curr Drug Metab 2003;4:223-39.
14. da Costa GG, McDaniel-Hamilton LP, Heflich RH, Marques MM, Beland FA. DNA adduct formation and mutant induction in Sprague-Dawley rats treated with tamoxifen and its derivatives. Carcinogenesis 2001;22:1307-15.
15. Carthew P, Edwards RE, Nolan BM, et al. Tamoxifen induces endometrial and vaginal cancer in rats in the absence of endometrial hyperplasia. Carcinogenesis 2000;21:793-7.
16. Beland FA, McDaniel LP, Marques MM. Comparison of the DNA adducts formed by tamoxifen and 4-hydroxytamoxifen in vivo. Carcinogenesis 1999;20:471-7.
17. Carmichael PL, Sardar S, Crooks N, et al. Lack of evidence from HPLC 32P-post-labelling for tamoxifen-DNA adducts in the human endometrium. Carcinogenesis 1999;20:339-42.
18. Carmichael PL, Ugwumadu AH, Neven P, Hewer AJ, Poon GK, Phillips DH. Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res 1996;56:1475-9.
19. Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science 2002;295:2465-8.
20. Shah YM, Rowan BG. The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor {a} promoter interaction and elevated steroid receptor coactivator 1 activity. Mol Endocrinol 2005;19:732-48.
21. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001;93:684-90.
22. Osborne CK, Bardou V, Hopp TA, et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003;95:353-61.
23. Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004;96:926-35.
24. Benz CC, Scott GK, Sarup JC, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1993;24:85-95.
25. Lu Y, Czerwenka K, Heuss F. Amplification and expression of c-erbB2 oncogene in normal, hyperplastic, and malignant endometria. Zhonghua Fu Chan Ke Za Zhi 1996;31:656-9.
26. Cianciulli AM, Guadagni F, Marzano R, et al. HER-2/neu oncogene amplification and chromosome 17 aneusomy in endometrial carcinoma: correlation with oncoprotein expression and conventional pathological parameters. J Exp Clin Cancer Res 2003;22:265-71.
27. Santin AD, Bellone S, O'Brien TJ, Pecorelli S, Cannon MJ, Roman JJ. Current treatment options for endometrial cancer. Expert Rev Anticancer Ther 2004;4:679-89.
28. Gottardis MM, Jordan VC. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 1988;48:5183-7.
29. Yao K, Lee ES, Bentrem DJ, et al. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 2000;6:2028-36.
30. O'Regan RM, England ME, MacCreger JI, et al. Laboratory models of breast and endometrial cancer to develop strategies for antiestrogen therapy. Breast Cancer 1998;5:211-7.
31. Robinson SP, Jordan VC. Antiestrogenic action of toremifene on hormone-dependent, -independent, and heterogeneous breast tumor growth in the athymic mouse. Cancer Res 1989;49:1758-62.
32. O'Regan RM, Cisneros A, England GM, et al. Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. J Natl Cancer Inst 1998;90:1552-8.
33. O'Regan RM, England ME, MacCreger JI, et al. Laboratory models of breast and endometrial cancer to develop strategies for antiestrogen therapy. Breast Cancer 1998;5:211-7.
34. Schafer JM, Lee ES, O'Regan RM, Yao K, Jordan VC. Rapid development of tamoxifen-stimulated mutant p53 breast tumors (T47D) in athymic mice. Clin Cancer Res 2000;6:4373-80.
35. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001;93:1852-7.
36. Dupont J, Le Roith D. Insulin-like growth factor 1 and oestradiol promote cell proliferation of MCF-7 breast cancer cells: new insights into their synergistic effects. Mol Pathol 2001;54:149-54.
37. Valentinis B, Baserga R. IGF-I receptor signalling in transformation and differentiation. Mol Pathol 2001;54:133-7.
38. Levin ER. Cell localization, physiology, and non-genomic actions of estrogen receptors. J Appl Physiol 2001;91:1860-7.
39. Song RX, Barnes CJ, Zhang Z, Bao Y, Kumar R, Santen RJ. The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor α to the plasma membrane. Proc Natl Acad Sci U S A 2004;101:2076-81.
40. Osipo C, Gajdos C, Liu H, Chen B, Jordan VC. Paradoxical Action of fulvestrant on estradiol-induced tumor regression of tamoxifen-stimulated breast cancer. J Natl Cancer Inst 2003.
41. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
42. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
43. Bunone G, Briand PA, Miksicek RJ, Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 1996;15:2174-83.
44. Sun M, Paciga JE, Feldman RI, et al. Phosphatidylinositol-3-OH kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor α (ERα) via interaction between ERα and PI3K. Cancer Res 2001;61:5985-91.
45. Kato S, Endoh H, Masuhiro Y, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995;270:1491-4.
46. Tartare-Deckert S, Murdaca J, Sawka-Verhelle D, Holt KH, Pessin JE, Van Obberghen E. Interaction of the molecular weight 85K regulatory subunit of the phosphatidylinositol 3-kinase with the insulin receptor and the insulin-like growth factor-1 (IGF-I) receptor: comparative study using the yeast two-hybrid system. Endocrinology 1996;137:1019-24.
47. Skolnik EY, Lee CH, Batzer A, et al. The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling. EMBO J 1993;12:1929-36.
48. Merchant JL, Du M, Todisco A. Sp1 phosphorylation by Erk 2 stimulates DNA binding. Biochem Biophys Res Commun 1999;254:454-61.
49. Milanini-Mongiat J, Pouyssegur J, Pages G. Identification of two Sp1 phosphorylation sites for p42/p44 mitogen-activated protein kinases: their implication in vascular endothelial growth factor gene transcription. J Biol Chem 2002;277:20631-9.
50. Benasciutti E, Pages G, Kenzior O, Folk W, Blasi F, Crippa MP. MAPK and JNK transduction pathways can phosphorylate Sp1 to activate the uPA minimal promoter element and endogenous gene transcription. Blood 2004;104:256-62.
51. Lang JC, Whitelaw B, Talbot S, Wilkie NM. Transcriptional regulation of the human c-myc gene. Br J Cancer Suppl 1988;9:62-6.
52. Liao DJ, Dickson RB. c-Myc in breast cancer. Endocr Relat Cancer 2000;7:143-64.
53. Safe S. Transcriptional activation of genes by 17 β-estradiol through estrogen receptor-Sp1 interactions. Vitam Horm 2001;62:231-52.
54. Raspollini MR, Mecacci F, Paglierani M, Marchionni M, Taddei GL. HER2/neu oncogene in uterine carcinosarcoma on tamoxifen therapy. Pathol Res Pract 2005;201:141-4.